SUMMARY The risk of adverse cardiovascular events is higher in persons with electrocardiographic evidence of left ventricular hypertrophy, and the decision to treat patients with antihypertensive drugs is often determined by the presence of hypertrophy. In this study a number of electrocardiographic criteria for detection of left ventricular hypertrophy were applied to a population of 85 hypertensive subjects in an ongoing outpatient hypertension evaluation and treatment program. Included were one set of criteria in common use and three sets of criteria employed in prospective clinical trials. The results were compared with those obtained by M-mode echocardiography and left ventricular wall thickness of 12 mm or more, which was taken as an indicator of hypertrophy. By this criterion, 34 patients (40%) had left ventricular hypertrophy. The most sensitive of the electrocardiographic criteria allowed detection of only 13 (38%) of those hypertensive subjects with anatomicalechocardiographic left ventricular hypertrophy. Although the echocardiogram is more time-consuming to obtain and more expensive than the electrocardiogram, its superior sensitivity suggests that the echocardiogram should be used for evaluating patients with high blood pressure, especially those without electrocardiographic evidence of left ventricular hypertrophy, to detect anatomical left ventricular hypertrophy. (Hypertension 7: 948-954, 1985) KEY WORDS hypertension echocardiography • left ventricular hypertrophy • electrocardiography I N the Framingham Study, the presence of defined electrocardiographic (ECG) evidence of left ventricular hypertrophy (LVH) in the hypertensive subjects was associated with a higher incidence of stroke and heart failure than if this evidence was absent. '• 2 This finding was also associated with increased incidence of coronary heart disease independent of the blood pressure level.' Similarly, in prospective clinical trials of drug intervention on the natural history of hypertension, such as the Veterans Administration Cooperative Study (VACS), 3 the benefit of vigorous therapy was more apparent in subjects with a variety of indicators of end-organ damage, including ECG evidence of LVH, than in those without. The ECG criteria for LVH have been used to exclude or stratify subjects in the design of clinical trials of drug treatment in hypertension. The Oslo study 4 excluded subjects with ECG evidence of LVH, and it is of interest that this abnormality developed only in untreated control paFrom the Department of Medicine, Medical College of Georgia, Augusta, Georgia.
electrocardiographic (ECG) evidence of left ventricular hypertrophy (LVH) in the hypertensive subjects was associated with a higher incidence of stroke and heart failure than if this evidence was absent. ' • 2 This finding was also associated with increased incidence of coronary heart disease independent of the blood pressure level.' Similarly, in prospective clinical trials of drug intervention on the natural history of hypertension, such as the Veterans Administration Cooperative Study (VACS), 3 the benefit of vigorous therapy was more apparent in subjects with a variety of indicators of end-organ damage, including ECG evidence of LVH, than in those without. The ECG criteria for LVH have been used to exclude or stratify subjects in the design of clinical trials of drug treatment in hypertension. The Oslo study 4 excluded subjects with ECG evidence of LVH, and it is of interest that this abnormality developed only in untreated control pa-tients during the trial. In the Hypertension Detection and Follow-up Program (HDFP) 5 ECG evidence of LVH, diagnosed on the basis of voltage criteria only, was present in 12.6% of subjects with initial diastolic blood pressure in the range of 90 to 104 mm Hg; 6 and if the presence of ST-T wave abnormalities was required for the diagnosis, only 3.4 to 3.6% of subjects had ECG evidence of LVH. 7 The age-adjusted 5-year mortality rate among 40-to 69-year-old men in the referred care group of the HDFP was two to three times as high in those with ECG evidence of LVH than in those without ECG evidence of LVH. 8 The clinical application of data from the more recent trials has been controversial.*" 15 It has been suggested that persons between 30 to 49 years of age with mild hypertension (diastolic blood pressure, 90-104 mm Hg) who do not have evidence of end-organ damage derive little benefit from antihypertensive therapy." If end-organ damage is critical, then accurate identification of LVH is of particular importance. However, the prospective clinical trials employed different ECG criteria, none of which are completely satisfactory, for the detection of LVH. The criteria employed in the VACS, the HDFP, and the Oslo study all rely on voltages produced by the left ventricle and on repolarization abnormalities. The point score system devised DETECTION OF HYPERTENSIVE LEFT VENTRICULAR HYPERTROPHY/Carr et al.
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by Romhilt and Estes (RE) 16 includes, in addition, consideration of the duration and axis of the QRS complex and gives substantial weight to the intra-atrial conduction abnormality commonly associated with LVH. The RE criteria were validated by a study of 360 autopsied hearts that employed a chamber dissection technique. In the latter study, reported by Romhilt et al., 17 the point score system had a sensitivity of 54% and a false-positive rate of only 3%.
Although the electrocardiograph is an excellent tool for the detection of acute ischemia, conduction abnormalities, and rhythm disturbances, it is not as sensitive for detecting anatomical LVH. Wall thickness is a simply obtained echocardiographic measure of anatomical LVH. Despite the availability of echocardiography, electrocardiography has been used in epidemiological studies for assessment and follow-up of subjects with hypertension and continues to be widely used by clinicians to detect LVH. Using wall thickness assessed by M-mode echocardiography as the standard for comparison, we evaluated the sensitivity, specificity, and predictive value of the ECG criteria for the detection of LVH devised for the VACS, the HDFP, the Oslo study, and the RE studies. 16 -"
Subjects and Methods
Eight cycles were measured to determine septal and left ventricular wall thickness, according to the standard leading edge to leading edge recommendations of the American Society of Echocardiography, 18 at the onset of the ORS complex at the level of the chordae tendineae of the mitral valve. For measurements of individual hypertensive subjects who underwent repeat echocardiography within days to 3 weeks while taking a placebo, the coefficient of variation at the 95% confidence limits was less than 5%. The echocardiograms were recorded by a highly skilled technician using an Ekoline 20 echograph (Smith-Kline, Palo Alto, CA, USA) equipped with a 2.2 MHz focused transducer for most of the studies or an Ultrasound System Imaging 772020A (Hewlett-Packard, Atlanta, GA, USA) equipped with a 2.5 MHz phased array transducer. The resolution of the Hewlett-Packard instrument is 1.5 mm. Satisfactory left ventricular echocardiograms from which measurements could be made from the original recordings were obtained in 129 of 188 (69%) consecutive studies in our laboratory. Only those echocardiograms with satisfactory identification of the mitral chordae tendineae with resolution adequate to measure septal and posterior left ventricular wall thickness were included. The normal echocardiographic values of Feigenbaum 19 were used. As in other studies, the upper limits of normal for septal or posterior ventricular thickness was taken to be 11 mm. 20 - 21 The echocardiographic and ECG studies were performed either on the same day or within 1 week of each other in 85% of the hypertensive subjects; in the other 15%, the studies were performed within 3 months of each other: eight within 1 month, three within 2 months, and two within 3 months.
For the purpose of this study, anatomical LVH was considered to be either septal or posterior left ventricular wall thickness of 12 mm or greater. Calculating left ventricular mass adds the possible errors of left ventricular internal diameter in diastole and the possible increases in mass by dilation rather than hypertrophy (increased wall thickness). The relation between left ventricular wall thickness and calculated left ventricular mass will be reported later. In addition, by excluding hypertensive subjects with evidence of previous or present myocardial infarction by ECG studies or wall motion abnormalities by echocardiographic studies, mitral valve prolapse, hemodynamically significant valvular disease, atrial fibrillation, or left bundle branch block, a ventricular wall thickness of 12 mm or greater should be a good index of anatomical LVH. Others have defined LVH in a similar manner.
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None of the hypertensive subjects studied were in congestive heart failure according to the definition applied in the Framingham Study. 27 The hypertensive subjects were those in an active ambulatory hypertensive population (800) who were observed by physicians of the hypertension section at the Medical College of Georgia. The project began in April 1980 and ended in August 1983, at which time 85 hypertensive subjects met the criteria just described and had adequate echocardiographic studies. Echocardiographic studies were ordered with no selection bias other than the above criteria to compare defined ECG to echocardiographic criteria for LVH. The 20% with LVH by RE ECG criteria 17 in this study was slightly less than the 30% previously reported for our hypertensive subjects. 28 The electrocardiograms were interpreted as either positive or negative for LVH according to the criteria of the RE studies, 16 n the VACS, 29 the Oslo study, 7 or the HDFP 6 by an independent observer who had no knowledge of the echocardiographic results (Table 1) . A score of 5 or more by RE criteria was defined as LVH (Table 2 ). With the echocardiogram as the standard, the sensitivity, specificity, positive predictive value, and negative predictive value of each of the ECG criteria were calculated by standard methods. •Reduced to 1 point if the patient is receiving digitalis.
Results
This study group included 48% black and 47% female hypertensive subjects. Age, sex, race, blood pressure level, and duration of hypertension characteristics are shown in Table 3 .
The findings from the comparison of the ECG and echocardiographic criteria are displayed in Table 4 . Of the 85 patients who met our entry criteria, 34 patients (40%) had evidence of LVH by echocardiogram and 51 patients (60%) had normal wall thickness. Antihypertensive drugs were part of the treatment regimen for 57% of those without and 99% of those with anatomical LVH. Compared with those without anatomical LVH, those with anatomical LVH had been hypertensive for a longer time and were considered more severe (higher diastolic pressures; see Table 3 ). They also were older. By chi-square analysis, the race composition was not significantly different for those with as compared to those without anatomical LVH (see Table 3 ). Table 5 shows the performance of each set of ECG criteria for LVH when the echocardiogram was used as the standard. Fewer hypertensive subjects had LVH by the various ECG criteria than were detected by echocardiography: RE, 17 (20%); HDFP, 14 (16.5%); VACS, 13 (15.2%); and Oslo study, 5 (5.9%). 12 Changing the RE score cutoff from 5 to 4 added only a single false-positive result and did not substantially change the data. Because there were some false-positive ECG diagnoses, the true incidence of LVH detected by electrocardiography was even less: RE, 13 (15.2%); HDFP, 7 (8.2%); VACS, 7 (8.2%); and Oslo study, 4 (4.7%). Table 5 also shows that the sensitivity was lowest and the false-negative rate was highest for the Oslo study criteria, but were similar for all. Specificity was adequate for all of the ECG criteria; the false-positive rate was lowest with the Oslo study criteria (2%) and similar (8-14%) for the other criteria. The positive and negative predictive values were highest with the RE criteria and lowest with the HDFP criteria; however, all were similar. Overall, the pattern of sensitivity, specificity, accuracy, and predictive value was best for the RE criteria. However, the sensitivity and specificity of each set of ECG criteria were not adequate for the reliable detection of anatomical LVH.
Discussion
These data comparing the criteria used in the RE studies, 1617 the VACS, 3 the Oslo study, 4 and the HDFP 5 -6 with an echocardiographic standard in the Numbers in parentheses indicate percentage. DBP = diastolic blood pressure; LVH = left ventricular hypertrophy; NS = not significant; Pj = probability of differences in characteristics for those with LVH versus those without LVH; P 2 = probability of differences in characteristics for those with no LVH comparing use or nonuse of antihypertensive drug; DBP ± SE = mean (mm Hg) ± SE of group when DBP measured at or within 2 days of echocardiographic study.
•Represents the DBP level for 75% of all office visits the year preceding the echocardiographic study. same hypertensive subjects indicate that the criteria used in various clinical trials do not confirm or exclude the presence of anatomical LVH with an adequate degree of sensitivity or accuracy. When hypertensive subjects with LVH are to be excluded in order to define a population with mild hypertension, as in the Oslo trial, a substantial number may have anatomical LVH even though the ECG criteria are not fulfilled. Other investigators have reported similar findings in necropsy series 3132 and in living patients. 31 Similarly, stratification of hypertensive subjects in the HDFP according to the presence of ECG evidence of LVH causes substantial misclassification from an anatomical point of view. The prognostic importance of anatomical LVH and the influence of pharmacological therapy on this prognosis remain unresolved by the available clinical trials.
Although by virtue of its low cost, rapid performance, and universal availability, the electrocardiograph is a practical instrument for clinical trials, these data suggest that echocardiography should be employed in future trials if the prognostic importance of anatomical LVH is to be clarified. It remains true that ECG evidence of LVH has prognostic importance, but the commonly employed voltage and ST-T criteria may be detecting some electrophysiological characteristic other than anatomical LVH. On the other hand, there is evidence that anatomical LVH is the consequence of sustained recurrent pressure loads, and its presence suggests the need for treatment even if casual office blood pressures are in the range of 90 to 104 mm Hg. 33 In this study, the RE criteria were the most sensitive, although the sensitivity was less than that observed in the original validation study 17 because an RE score of 5 or more rather than 4 or more was used. In addition, the sensitivity and specificity of ECG criteria may also be influenced by patient selection. These are two possible explanations for the discrepancy between the 38% sensitivity found in the present study and the 54% reported by Romhilt et al. 17 in 1969. Table 6 summarizes studies in which the ECG evidence of LVH criteria described by Romhilt et al. 17 and Sokolow and Lyon 34 were assessed by comparison with anatomical LVH detected by autopsy or echocardiography.
Selection of subjects can influence the percent with anatomical LVH. The hypertensive subjects in our study are being followed up in our outpatient treatment program. They are 48% black and 47% women, which compares to our initial population of 86% blacks and 63% women. 36 Thirty percent of that earlier population had ECG evidence of LVH, while only 20% had ECG evidence of LVH in the present group. The lower percent with ECG evidence of LVH may be due to fewer blacks in the present group. Our data show that, compared with those hypertensive subjects without anatomical LVH, those with anatomical LVH were older with higher levels of diastolic blood pressure of longer duration. Those with anatomical LVH were 59% black as compared to 39% black without anatomical LVH, but the difference was not statistically significant. All but one of those with anatomical LVH were receiving antihypertensive drug treatment as compared to 57% of those without anatomical LVH. There was no selection bias for the hypertensive subjects in this study other than those mentioned in the methods section. Our In subject selection based on autopsy -not hypertension, subjects were selected on the basis of autopsy and ECG evidence within 3 to 6 months of death. LVH = left ventricular hypertrophy; ECG = electrocardiogram; LV = left ventricular; R4 or 5 = > 4 points; R5 = a 5 points.
•Criteria based on the point score system described by Romhilt et al. 17 (R) or Sokolow and Lyon 34 (S). tThe LV wall thickness was highly correlated with LV mass. tThe LV wall thickness was highly correlated with LV mass and with ECG.
present outpatient hypertensive population is the same as the study group in terms of race and sex. Others believe blacks as compared to whites with hypertension have increased left ventricular mass; however, these same investigators could not demonstrate differences in septal and left ventricular wall thickness. 37 The sensitivity of electrocardiography in detecting LVH may be influenced by the duration and severity of hypertension such that the selection process involves hypertensive subjects with anatomical LVH of varying severity, which will influence the sensitivity of any ECG criteria. The sensitivity of the RE criteria for hypertensive subjects from treatment programs varies from 6% 23 to 12% 22 to 19% 25 to the 38% found in the present study (see Table 4 ). A recent study of the RE criteria in regard to anatomical LVH by left ventricular mass showed a sensitivity of 34% for RE score of 5 or more (similar to ours of 38%) and 48% for a score of 4 or more. 38 The data are similar to those in Table 6 . Only 45% of these subjects had hypertension; the others had mitral valve prolapse, atherosclerotic cardiovascular disease, pericardial disease, diabetes mellitus, cardiomyopathy, bacterial endocarditis, miscellaneous conditions, and no cardiac disease.
Antihypertensive drugs that lower blood pressure may decrease R-wave amplitude but do not change intrinsicoid deflection or repolarization changes over the left ventricle. 39 Repolarization changes do seem to be more specific for LVH, especially when patients with known coronary heart disease are excluded.
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On a weighted basis, the mean sensitivity in these studies (see Table 6 ) was 37%, the mean specificity was 94%, and the incidence of anatomical LVH was 45%. These values are quite similar to those obtained using the RE criteria in the present study of hypertensive subjects observed in our ongoing ambulatory hypertension treatment program: sensitivity, 38%; specificity, 92%; and incidence of anatomical LVH 40%.
Detection of anatomical LVH by echocardiography demands a standardized procedure to keep left ventricular wall thickness measurement errors to a minimum. Observer (measurement) and patient (biological) variations can cause errors and must be controlled. Patient variations are kept to a minimum by the exclusions noted in the methods section. In addition, a possible error owing to heart rate variation was controlled by the fact that no studies were performed if bradycardia or tachycardia was present. The procedure was performed in a quiet room after the subject had been resting quietly for 5 to 10 minutes. Only subjects with high resolution studies were accepted. Adequate measurements cannot be obtained in about one third of adult subjects. We have used the recommendations of the American Society of Echocardiography 18 to keep measurement errors to a minimum. Angulation of the sonic beam can cause errors. These errors are greater for left ventricular minor axis diameter than posterior wall thickness. 42 A standard intercostal space and the anatomical landmark of the chordae tendineae minimize this type of measurement error for posterior wall thickness and for the septum (although not as well). There are the additional problems of septal measurements caused by right-sided echoes from the tricuspid chordae and occasional dropouts of left-sided septal echoes. Because of greater error possible in the diagnosis of anatomical LVH using septal thickness of 12 mm or greater, a septal wall thickness of 13 mm or greater or a posterior left ventricular wall of 12 mm or greater was required. The results (in parentheses to the right of each ECG criteria column in Table 5 ) are essentially the same.
The measure at the onset of the QRS complex and of several cycles minimizes observer and subject measurement errors. When the equipment resolution is at 1 mm and wall thickness is 11 mm or less, then the error has to be at least 10% or more. 43 Studies on reproducibility and variability report that the percentage error for wall thickness is higher than that for left ventricular minor axis diameter. 42 -44 " 46 However, reproducibility of a wall thickness of 12 mm or more or of cardiac disease as compared to a wall thickness of 11 mm or less of normal subjects is much better, and the error is usually less than lO'fo. Although we do not have our own data on left ventricular wall thickness measurements in normal subjects, we have used 11 mm as the upper limit of normal, based on data from other reported studies. 19 " 21 This arbitrary cutoff of 11 mm or less versus 12 mm or more also allows for better reproducibility of the measurements, especially for those hypertensive subjects with a wall thickness of 12 mm or more. Because patient selection excluded those with known myocardial infarction, mitral valve prolapse, or significant valvular heart disease and the errors induced by differences in sonic beam angle are less for wall thickness as compared to ventricular diameter, we believe that wall thickness measurement is a good index for detection of anatomical LVH. However, high quality, accurate, and reproducible echocardiographic studies depend on the observer, equipment, and patient conditions. The methods must be highly standardized. The observers involved in the measurement must be well trained and skilled, and the instrument must be designed for cardiac studies. We suggest that the criteria used for standardization should be based on the data in our methods section as well as those from Sahn et al., 18 Popp et al. , 42 and the Echocardiography Study Group. 48 Only if such conditions are met can echocardiographic studies be used to determine the accurate presence or absence of anatomical LVH.
Although the prognostic importance of anatomical evidence of LVH as distinct from ECG evidence of LVH remains to be clarified, the need to detect early evidence of cardiac hypertrophy in subjects with mild hypertension requires that echocardiography should be more widely used to detect this type of end-organ damage. It is of interest that the 1984 Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure 49 recommends the use of echocardiographic studies to determine if the myocardium of the hypertensive child is thickened. Pharmacotherapy is recommended if the myocardium is thickened. 49 Ventricular wall thickness probably should be corrected for age and body surface area. 20 - 50 When septal and posterior wall thickness data were corrected for age and body surface area in the hypertensive subjects in this study, there were no differences in the numbers with and without anatomical LVH as defined in the methods section. Our results indicate that left ventricular wall thickness, measured by a highly standardized and controlled technique by a highly qualified observer, is a method of detecting anatomical LVH and should be used, especially in the absence of ECG evidence of LVH.
